Comparison of the Effectiveness of Ceftobiprole and Vancomycin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus-Induced Meningitis

dc.authoridSipahi, Oguz Resat/0000-0002-1243-2746;
dc.contributor.authorMermer, Sinan
dc.contributor.authorTurhan, Tuncer
dc.contributor.authorBolat, Elif
dc.contributor.authorAydemir, Sohret
dc.contributor.authorSipahi, Hilal
dc.contributor.authorSipahi, Oguz Resat
dc.date.accessioned2024-08-31T07:49:54Z
dc.date.available2024-08-31T07:49:54Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: Nosocomial meningitis may occur after procedures affecting the central nervous system or following traumatic injury. The causative infectious organism is commonly Staphylococcus aureus, a Gram-positive bacterium. The aim of the present study was to compare the effectiveness of two antibacterial agents, ceftobiprole and vancomycin, in an animal model of methicillin-resistant S. aureus (MRSA) meningitis. Method: The strain of MRSA used was ATCC 43300. The animals were divided into three groups and infected intracisternally with MRSA. Controls received no antibiotherapy while the ceftobiprole group received 25 mg/kg and the vancomycin group received 20 mg/kg intravenously. Blood and cerebrospinal fluid (CSF) samples were collected at three time points. All animals were euthanized at 73 h after start of treatment. Results: There was a significant difference (p < 0.05) between both treatment groups and the control animals at 24 h (drug trough) and 73 h (1 h after third dose) after start of treatment in terms of CSF bacterial levels. At 73 h, there was a significant difference in survival between the control group and the two treatment groups but no difference between the treated animal survival rates. Conclusion: Intravenous treatment with ceftobiprole and vancomycin appears to be equally effective in a rabbit model of MRSA meningitis.en_US
dc.description.sponsorshipBasilea Pharmaceutica [101997]en_US
dc.description.sponsorshipThis study was supported by a grant from Basilea Pharmaceutica (#101997).en_US
dc.identifier.doi10.1159/000527531
dc.identifier.issn0009-3157
dc.identifier.issn1421-9794
dc.identifier.pmid38697031en_US
dc.identifier.scopus2-s2.0-85193525476en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1159/000527531
dc.identifier.urihttps://hdl.handle.net/11454/105019
dc.identifier.wosWOS:001227713800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofChemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectNosocomial Meningitisen_US
dc.subjectVancomycinen_US
dc.subjectCeftobiproleen_US
dc.subjectAnimal Modelen_US
dc.subjectPharmacokineticsen_US
dc.titleComparison of the Effectiveness of Ceftobiprole and Vancomycin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus-Induced Meningitisen_US
dc.typeArticleen_US

Dosyalar